Zobrazeno 1 - 10
of 127
pro vyhledávání: '"François‐Xavier Mahon"'
Autor:
Gabriel Etienne, Carole Faberes, Fréderic Bauduer, Didier Adiko, François Lifermann, Corinne Dagada, Caroline Lenoir, Anna Schmitt, Emilie Klein, Marie‐Pierre Fort, Fontanet Bijou, Beatrice Turcq, Fanny Robbesyn, Françoise Durrieu, Laura Versmée, Samia Madene, Marius Moldovan, Sandrine Katsahian, Anais Charles‐Nelson, Axelle Lascaux, François‐Xavier Mahon, Stéphanie Dulucq
Publikováno v:
Cancer Medicine, Vol 10, Iss 11, Pp 3635-3645 (2021)
Abstract Background Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic phase chronic myeloid leukemia (CP‐CML) patients who had achieved a sustained deep molecular response. Based on the results of discontinuation trials, recomm
Externí odkaz:
https://doaj.org/article/e95e922c9ffa45b69d31d079ecb40d5f
Autor:
Stéphanie Dulucq, Franck E. Nicolini, Delphine Rea, Pascale Cony-Makhoul, Aude Charbonnier, Martine Escoffre-Barbe, Valérie Coiteux, Pascal Lenain, Françoise Rigal-Huguet, Jixing Liu, Agnès Guerci-Bresler, Laurence Legros, Jean-Christophe Ianotto, Martine Gardembas, Pascal Turlure, Viviane Dubruille, Philippe Rousselot, Juliana Martiniuc, Henry Jardel, Hyacinthe Johnson-Ansah, Bertrand Joly, Tawfiq Henni, Emilie Cayssials, Patricia Zunic, Marc G. Berger, Bruno Villemagne, Fanny Robbesyn, Stephane Morisset, François-Xavier Mahon, Gabriel Etienne
Publikováno v:
Haematologica, Vol 107, Iss 12 (2022)
Discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia is feasible in clinical practice based on recently published international recommendations. Nevertheless, factors predictive of molecular recurrence have not been
Externí odkaz:
https://doaj.org/article/28263e36eb3a4f589724f3b48b82115e
Autor:
Matthieu Lewis, Valérie Prouzet‐Mauléon, Florence Lichou, Elodie Richard, Richard Iggo, Béatrice Turcq, François‐Xavier Mahon
Publikováno v:
Cancer Medicine, Vol 9, Iss 18, Pp 6739-6751 (2020)
Abstract Understanding resistance mechanisms in cancer is of utmost importance for the discovery of novel “druggable” targets. Efficient genetic screening, now even more possible with CRISPR‐Cas9 gene‐editing technology, next‐generation seq
Externí odkaz:
https://doaj.org/article/ee2e1b61d9ac4c1882f8c1d944da62fe
Autor:
Anne Trinh, Raeeka Khamari, Quentin Fovez, François-Xavier Mahon, Béatrice Turcq, Didier Bouscary, Patrice Maboudou, Marie Joncquel, Valérie Coiteux, Nicolas Germain, William Laine, Salim Dekiouk, Sandrine Jean-Pierre, Veronique Maguer-Satta, Bart Ghesquiere, Thierry Idziorek, Bruno Quesnel, Jerome Kluza, Philippe Marchetti
Publikováno v:
Molecular Metabolism, Vol 55, Iss , Pp 101410- (2022)
Objective: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, eviden
Externí odkaz:
https://doaj.org/article/bffd69c235194487adfbf1e0576e3453
Autor:
Pierre‐Yves Dumas, Emilie Bérard, Claire Bréal, Stéphanie Dulucq, Delphine Réa, Franck Nicolini, Edouard Forcade, Melody Dufossée, Jean‐Max Pasquet, Béatrice Turcq, Audrey Bidet, Noel Milpied, Julie Déchanet‐Merville, Xavier Lafarge, Gabriel Etienne, François‐Xavier Mahon, French Intergroup in Chronic Myeloid Leukemia
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 4976-4985 (2019)
Abstract Background Natural Killer (NK) cells are innate lymphoid cells that can be cytotoxic toward a large panel of solid tumors and hematological malignancies including chronic myeloid leukemia (CML). Such a cytotoxicity depends on various recepto
Externí odkaz:
https://doaj.org/article/fde024de99b941a08e4dd670a8681016
Autor:
Gabriel Etienne, Stéphanie Dulucq, Françoise Huguet, Anna Schmitt, Axelle Lascaux, Sandrine Hayette, Marie‐Pierre Fort, Pierre Sujobert, Fontanet Bijou, Stéphane Morisset, Suzanne Tavitian, Audrey Bidet, Beatrice Turcq, Fanny Robbesyn, Claudine Chollet, Francis Belloc, Françoise Durrieu, François‐Xavier Mahon, Franck E. Nicolini
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5173-5182 (2019)
Abstract Purpose To assess the incidence of BCR‐ABL kinase domain (KD) mutation detection and its prognostic significance in chronic phase chronic myeloid leukemia (CP‐CML) patients treated with tyrosine kinase inhibitors (TKIs). Patients and Met
Externí odkaz:
https://doaj.org/article/6e01c6179d7a4668b2becca6369a87e0
Autor:
Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1676 (2022)
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance. We decided to conduct a prospective
Externí odkaz:
https://doaj.org/article/133d20dc3fef461aa82f821be11325df
Autor:
Florence Lichou, Sébastien Orazio, Stéphanie Dulucq, Gabriel Etienne, Michel Longy, Christophe Hubert, Alexis Groppi, Alain Monnereau, François-Xavier Mahon, Béatrice Turcq
Publikováno v:
Human Genomics, Vol 13, Iss 1, Pp 1-11 (2019)
Abstract Background Targeted therapies have greatly improved cancer patient prognosis. For instance, chronic myeloid leukemia is now well treated with imatinib, a tyrosine kinase inhibitor. Around 80% of the patients reach complete remission. However
Externí odkaz:
https://doaj.org/article/afaf3dfcb3be4dcbb71a9c322a47951a
Autor:
Pierre-Yves Dumas, Olivier Mansier, Valerie Prouzet-Mauleon, Junji Koya, Arnaud Villacreces, Philippe Brunet de la Grange, Damien Luque Paz, Audrey Bidet, Jean-Max Pasquet, Vincent Praloran, Franck Salin, Mineo Kurokawa, François-Xavier Mahon, Bruno Cardinaud, Eric Lippert
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Atypical Myeloproliferative Neoplasms (aMPN) share characteristics of MPN and Myelodysplastic Syndromes. Although abnormalities in cytokine signaling are common in MPN, the pathophysiology of atypical MPN still remains elusive. Si
Externí odkaz:
https://doaj.org/article/4794d25d55f54eb09f7966c3979775b0
Autor:
Gabriel Etienne, Stéphanie Dulucq, Fréderic Bauduer, Didier Adiko, François Lifermann, Corinne Dagada, Caroline Lenoir, Anna Schmitt, Emilie Klein, Samia Madene, Marie-Pierre Fort, Fontanet Bijou, Marius Moldovan, Beatrice Turcq, Fanny Robbesyn, Françoise Durrieu, Laura Versmée, Sandrine Katsahian, Carole Faberes, Axelle Lascaux, François-Xavier Mahon
Publikováno v:
Cancers, Vol 12, Iss 9, p 2521 (2020)
Background: Tyrosine Kinase Inhibitors (TKIs) discontinuation in patients who had achieved a deep molecular response (DMR) offer now the opportunity of prolonged treatment-free remission (TFR). Patients and Methods: Aims of this study were to evaluat
Externí odkaz:
https://doaj.org/article/262ad16b203b43079c58ea0818468c2b